Diagnostic Performance and Safety of <sup>18</sup> F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT)
Ashesh B. Jani(University of California San Diego), Katherine Zukotynski(Unknown), Ian Cox(The University of Texas MD Anderson Cancer Center), Rik Somford, Mary A. Lokuta, Phillip H. Kuo(Knowledge Unlatched (Germany)), Michael L. Cher(The Barbara Ann Karmanos Cancer Institute), Giuseppe Esposito, David Gauden(Emory University), William C. Lavely, Bridget F. Koontz(AdventHealth Orlando), Mohamad E. Allaf(Johns Hopkins University), Benjamin A. Gartrell, Bital Savir-Baruch, Morand Piert, Benjamin Lowentritt, Peter Gardiner(University of Turku), Karen Mourtzikos, Edward Uchio(University of California, Irvine), Norbert Avril(University Hospitals of Cleveland), Lale Kostakoğlu, R. H. C. Penny, Jeff M. Michalski(Washington University in St. Louis), David M. Schuster(Emory University), Barry A. Siegel(Washington University in St. Louis), Soroush Rais‐Bahrami(University of Alabama at Birmingham), Ashutosh Tewari(Icahn School of Medicine at Mount Sinai), Gregory Ravizzini(The University of Texas MD Anderson Cancer Center), Don C. Yoo(Brown University), Mark T. Fleming(Virginia Oncology Associates), Brian F. Chapin(The University of Texas MD Anderson Cancer Center), Matthew F. Covington(Intermountain Healthcare), Russell K. Pachynski, Andrei S. Purysko, Peter J. Boström(University of Turku), Ryan Avery, Phillip Davis, Matthew P. Miller, Matthew D. Kay, Daniel R. Saltzstein(Urology San Antonio), Przemyslaw Twardowski(Saint John's Health Center), Rick Hermsen, Helen Barker, Ing Han Liem, David Josephson(Cedars-Sinai Medical Center), Albert Chau(Blue Earth Diagnostics (United Kingdom)), Diane Chisholm, Laurence Belkoff
Cited by 65
Related Papers
Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
|Journal of Clinical Oncology|2013|594
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non–small cell lung cancer
|Journal of Thoracic and Cardiovascular Surgery|2003|301
Concurrent Chemotherapy and Intensity-Modulated Radiation Therapy for Anal Canal Cancer Patients: A Multicenter Experience
|Journal of Clinical Oncology|2007|268